CDKN2A and pulmonary fibrosis: Taken together, these results demonstrate that our senolytic HTS identified a compound that preferentially targets p16Ink4a+ fibroblasts from fibrotic lungs, which was subsequently validated in vivo and ex vivo in mouse models of lung fibrosis and human IPF samples, respectively.